Shuang Li1, Ding Ma2, Hao-Hong Shi3, Ke-Da Yu2, Qiang Zhang1. 1. Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110042, China. 2. Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Children's Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3. Department of Anesthesiology, Children's Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Abstract
BACKGROUND: For triple negative breast cancer (TNBC), the optimal time from surgery to initiation of adjuvant chemotherapy is controversial. We investigated the influence of time to adjuvant chemotherapy on outcome in TNBC patients. METHODS: Female patients with stage I-IIIa operable TNBC between 2006 and 2008 in our institutions were included. A total of 331 patients were divided into 3 groups according to the time to adjuvant chemotherapy: ≤30, 31-60, and >60 days. Relapse free survival (RFS) were calculated and compared. RESULTS: Prolonged delay of initiation of adjuvant chemotherapy (≤30 versus >60 days) significantly decreased the RFS in our TNBC cohort [adjusted hazard ratio (HR) of 2.39; 95% confidence interval (CI), 1.13-5.07, P=0.02]. While a moderate delay (≤30 versus 31-60 days) did not significantly influence RFS in all TNBC patients, it did compromise survival in lymph node positive patients (P=0.04). CONCLUSIONS: Longer delay of adjuvant chemotherapy was associated with worse survival in TNBC patients. Early initiation of adjuvant chemotherapy should be considered, especially for relatively high risk node positive TNBCs.
BACKGROUND: For triple negative breast cancer (TNBC), the optimal time from surgery to initiation of adjuvant chemotherapy is controversial. We investigated the influence of time to adjuvant chemotherapy on outcome in TNBC patients. METHODS: Female patients with stage I-IIIa operable TNBC between 2006 and 2008 in our institutions were included. A total of 331 patients were divided into 3 groups according to the time to adjuvant chemotherapy: ≤30, 31-60, and >60 days. Relapse free survival (RFS) were calculated and compared. RESULTS: Prolonged delay of initiation of adjuvant chemotherapy (≤30 versus >60 days) significantly decreased the RFS in our TNBC cohort [adjusted hazard ratio (HR) of 2.39; 95% confidence interval (CI), 1.13-5.07, P=0.02]. While a moderate delay (≤30 versus 31-60 days) did not significantly influence RFS in all TNBC patients, it did compromise survival in lymph node positive patients (P=0.04). CONCLUSIONS: Longer delay of adjuvant chemotherapy was associated with worse survival in TNBC patients. Early initiation of adjuvant chemotherapy should be considered, especially for relatively high risk node positive TNBCs.
Entities:
Keywords:
Timing; adjuvant chemotherapy; survival; triple-negative breast cancer
Authors: M Colleoni; M Bonetti; A S Coates; M Castiglione-Gertsch; R D Gelber; K Price; C M Rudenstam; J Lindtner; J Collins; B Thürlimann; S Holmberg; A Veronesi; G Marini; A Goldhirsch Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor Journal: J Clin Oncol Date: 2014-01-27 Impact factor: 44.544
Authors: Erik Heeg; Perla J Marang-van de Mheen; Marissa C Van Maaren; Kay Schreuder; Rob A E M Tollenaar; Sabine Siesling; Monique E M M Bos; Marie-Jeanne T F D Vrancken Peeters Journal: Int J Cancer Date: 2019-11-28 Impact factor: 7.396
Authors: Christine Brezden-Masley; Kelly E Fathers; Megan E Coombes; Behin Pourmirza; Cloris Xue; Katarzyna J Jerzak Journal: Cancer Med Date: 2020-08-30 Impact factor: 4.452